RNA-seq data analysis from the collections of prostate cancer patient samples11 validated the upregulation of the MYCN gene in the NEPC cohort, but not in AR-high prostate cancer (ARPC), AR-low prostate cancer (ARLPC), amphicrine prostate cancer (AMPC), and double negative prostate cancer (DNPC). The gene discussed is MYCN; the disease is prostate carcinoma.